Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Transcriptional control of viral gene therapy by cisplatin
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
James O. Park, … , Donald W. Kufe, Ralph R. Weichselbaum
Published August 1, 2002
Citation Information: J Clin Invest. 2002;110(3):403-410. https://doi.org/10.1172/JCI15548.
View: Text | PDF
Article Genetics Article has an altmetric score of 4

Transcriptional control of viral gene therapy by cisplatin

  • Text
  • PDF
Abstract

Research Article

Authors

James O. Park, Carlos A. Lopez, Vinay K. Gupta, Charles K. Brown, Helena J. Mauceri, Thomas E. Darga, Abdullah Manan, Samuel Hellman, Mitchell C. Posner, Donald W. Kufe, Ralph R. Weichselbaum

×

Figure 2

Options: View larger image (or click on image) Download as PowerPoint
In vitro reporter assays. Luciferase reporter constructs were used to ev...
In vitro reporter assays. Luciferase reporter constructs were used to evaluate induction of the Egr1 promoter by IR or cisplatin. Minimal LA was detectable following transfection with either the pGL3 basic (negative control) or the pGL3 660 plasmid (minimal Egr1 promoter) constructs. (a) In Seg-1 cells transfected with pGL3 425, a 2.4-fold increase (P = 0.005) in relative LA was observed following exposure to IR (20 Gy), and a 2.0-fold increase (P = 0.005) was seen following exposure to cisplatin (50 μM). (b) In PROb cells transfected with pGL3 425, there was a 4.2-fold increase (P = 0.004) in relative LA following exposure to IR (20 Gy), and a 3.6-fold increase (P = 0.01) following exposure to cisplatin (50 μM). Data are reported as mean ± SEM.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
On 1 Facebook pages
7 readers on Mendeley
See more details